StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
6-factor scoring with sector-relative rank. Updated daily.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $5.58 | $5.50 | -1.43% | 0.0M |
| 05-12 | $5.43 | $5.16 | -4.97% | 0.1M |
| 05-13 | $5.23 | $5.16 | -1.34% | 0.0M |
| 05-14 | $5.16 | $5.15 | -0.19% | 0.0M |
| 05-15 | $5.11 | $4.85 | -5.09% | 0.0M |
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Each factor shows ATOS's percentile within the scored universe — observational ranking, not a recommendation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q3 2026 (Est.) Expected 2026-08-10 | Q3 2016 2016-09-30 | Q2 2016 2016-06-30 | Q1 2016 2016-03-31 | Annual 2015 2015-12-31 |
|---|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $1.76K |
Operating Income | Not available | $-5.44M | $-4.05M | $-2.33M | $-12.76M |
Net Income | Not available | $-3.85M | $-4.05M | $-2.33M | $-15.76M |
EPS (Diluted) | $-1.09 | Not available | Not available | Not available | Not available |
Total Assets | Not available | $6.28M | $3.28M | $5.10M | $6.24M |
Total Liabilities | Not available | Not available | Not available | Not available | $2.50M |
Cash & Equivalents | Not available | $4.39M | $1.19M | $2.88M | $3.72M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available | Not available |
Shares Outstanding | Not available | 3.79M | 39.57M | 38.82M | 2.18M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.